Skip to main content
Top
Published in: Familial Cancer 4/2020

01-10-2020 | osteoma | Short Communication

Highly aggressive thoracic desmoid tumors in adolescent siblings with fatal outcomes in an FAP kindred: a need for increased vigilance and intervention in at-risk AYAs

Authors: Mohamed M. Gad, Anne-Marie Langevin, Aaron J. Sugalski, Gail E. Tomlinson

Published in: Familial Cancer | Issue 4/2020

Login to get access

Abstract

Desmoid tumors are a manifestation of familial adenomatous polyposis (FAP), associated with mutation of the APC gene. Although considered benign tumors, desmoids can be aggressive and cause considerable morbidity. Known risk factors for desmoid tumor growth include location of mutations within the APC gene, family history of desmoid tumors, previous surgery, female gender, and pregnancy. Desmoids occur at diverse sites, commonly within the abdomen or at sites of previous surgery; thoracic desmoids are relatively uncommon. Reported here is a highly desmoid tumor-prone FAP family with a truncating mutation in the APC gene at codon 1550 (c.4648G>T) in which female siblings developed remarkably similar thoracic desmoids with highly aggressive tumor behavior during the onset of puberty, throughout adolescence, and in one sibling during and following pregnancy. Both siblings had a fatal outcome. This case underscores the potential for aggressive behavior of desmoids during adolescence and the need for close vigilance during the adolescent and young adult (AYA) age range in desmoid-prone FAP kindreds.
Literature
1.
go back to reference Half E, Bercovich D, Rozen P (2009) Familial adenomatous polyposis. Orphanet J Rare Dis 4:22CrossRef Half E, Bercovich D, Rozen P (2009) Familial adenomatous polyposis. Orphanet J Rare Dis 4:22CrossRef
2.
go back to reference Campos FG, Martinez CA, Novaes M, Nahas SC, Cecconello I (2015) Desmoid tumors: clinical features and outcome of an unpredictable and challenging manifestation of familial adenomatous polyposis. Fam Cancer 14(2):211–219CrossRef Campos FG, Martinez CA, Novaes M, Nahas SC, Cecconello I (2015) Desmoid tumors: clinical features and outcome of an unpredictable and challenging manifestation of familial adenomatous polyposis. Fam Cancer 14(2):211–219CrossRef
3.
go back to reference Martinez Trufero J, Pajares Bernad I, Torres Ramon I, Hernando Cubero J, Pazo Cid R (2017) Desmoid-type fibromatosis: who, when, and how to treat. Curr Treat Options Oncol 18(5):29CrossRef Martinez Trufero J, Pajares Bernad I, Torres Ramon I, Hernando Cubero J, Pazo Cid R (2017) Desmoid-type fibromatosis: who, when, and how to treat. Curr Treat Options Oncol 18(5):29CrossRef
4.
go back to reference Sinha A, Tekkis PP, Gibbons DC, Phillips RK, Clark SK (2011) Risk factors predicting desmoid occurrence in patients with familial adenomatous polyposis: a meta-analysis. Colorectal Dis 13(11):1222–1229CrossRef Sinha A, Tekkis PP, Gibbons DC, Phillips RK, Clark SK (2011) Risk factors predicting desmoid occurrence in patients with familial adenomatous polyposis: a meta-analysis. Colorectal Dis 13(11):1222–1229CrossRef
5.
go back to reference Fiore M, Coppola S, Cannell AJ, Colombo C, Bertagnolli MM, George S et al (2014) Desmoid-type fibromatosis and pregnancy: a multi-institutional analysis of recurrence and obstetric risk. Ann Surg 259(5):973–978CrossRef Fiore M, Coppola S, Cannell AJ, Colombo C, Bertagnolli MM, George S et al (2014) Desmoid-type fibromatosis and pregnancy: a multi-institutional analysis of recurrence and obstetric risk. Ann Surg 259(5):973–978CrossRef
6.
go back to reference Caspari R, Olschwang S, Friedl W, Mandl M, Boisson C, Boker T et al (1995) Familial adenomatous polyposis: desmoid tumours and lack of ophthalmic lesions (CHRPE) associated with APC mutations beyond codon 1444. Hum Mol Genet 4(3):337–340CrossRef Caspari R, Olschwang S, Friedl W, Mandl M, Boisson C, Boker T et al (1995) Familial adenomatous polyposis: desmoid tumours and lack of ophthalmic lesions (CHRPE) associated with APC mutations beyond codon 1444. Hum Mol Genet 4(3):337–340CrossRef
7.
go back to reference Koskenvuo L, Ristimaki A, Lepisto A (2017) Comparison of sporadic and FAP-associated desmoid-type fibromatoses. J Surg Oncol 116(6):716–721CrossRef Koskenvuo L, Ristimaki A, Lepisto A (2017) Comparison of sporadic and FAP-associated desmoid-type fibromatoses. J Surg Oncol 116(6):716–721CrossRef
8.
go back to reference Bocale D, Rotelli MT, Cavallini A, Altomare DF (2011) Anti-oestrogen therapy in the treatment of desmoid tumours: a systematic review. Colorectal Dis 13(12):e388–e395CrossRef Bocale D, Rotelli MT, Cavallini A, Altomare DF (2011) Anti-oestrogen therapy in the treatment of desmoid tumours: a systematic review. Colorectal Dis 13(12):e388–e395CrossRef
9.
go back to reference Toulmonde M, Pulido M, Ray-Coquard I, Andre T, Isambert N, Chevreau C et al (2019) Pazopanib or methotrexate-vinblastine combination chemotherapy in adult patients with progressive desmoid tumours (DESMOPAZ): a non-comparative, randomised, open-label, multicentre, phase 2 study. Lancet Oncol 20(9):1263–1272CrossRef Toulmonde M, Pulido M, Ray-Coquard I, Andre T, Isambert N, Chevreau C et al (2019) Pazopanib or methotrexate-vinblastine combination chemotherapy in adult patients with progressive desmoid tumours (DESMOPAZ): a non-comparative, randomised, open-label, multicentre, phase 2 study. Lancet Oncol 20(9):1263–1272CrossRef
10.
go back to reference Syngal S, Brand RE, Church JM, Giardiello FM, Hampel HL, Burt RW (2015) ACG clinical guideline: genetic testing and management of hereditary gastrointestinal cancer syndromes. Am J Gastroenterol 110(2):223–262CrossRef Syngal S, Brand RE, Church JM, Giardiello FM, Hampel HL, Burt RW (2015) ACG clinical guideline: genetic testing and management of hereditary gastrointestinal cancer syndromes. Am J Gastroenterol 110(2):223–262CrossRef
Metadata
Title
Highly aggressive thoracic desmoid tumors in adolescent siblings with fatal outcomes in an FAP kindred: a need for increased vigilance and intervention in at-risk AYAs
Authors
Mohamed M. Gad
Anne-Marie Langevin
Aaron J. Sugalski
Gail E. Tomlinson
Publication date
01-10-2020
Publisher
Springer Netherlands
Published in
Familial Cancer / Issue 4/2020
Print ISSN: 1389-9600
Electronic ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-020-00177-2

Other articles of this Issue 4/2020

Familial Cancer 4/2020 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine